Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.48 |
| ▸ | EP300 | Q09472 | 3/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190900 | 0.92 | BRD4 (0.41) | BRD4EP300BRD2BRD3BRDT | |
| SCHEMBL21191077 | 0.91 | BRD4 (0.49) | BRD4EP300BRD2BRD3BRDT | |
| SCHEMBL21191109 | 0.89 | BRD4 (0.40) | BRD4EP300BRD2BRD3BRDT | |
| SCHEMBL15069481 | 0.86 | BRD4 (0.48) | BRD4EP300MAPK14GSK3ACDK9 | |
| SCHEMBL21191120 | 0.84 | PTGS2 (0.47) | BRD4MAPK14PTGS2SCN9A | |
| SCHEMBL21191165 | 0.84 | TRPA1 (0.35) | BRD4EP300BRD2BRD3BRDT | |
| SCHEMBL21191117 | 0.83 | TRPA1 (0.37) | BRD4EP300 | |
| SCHEMBL21190861 | 0.82 | BRD4 (0.47) | BRD4EP300PTGS2SCN9A | |
| SCHEMBL16650187 | 0.82 | TRPA1 (0.40) | MAPK14 | |
| SCHEMBL16650965 | 0.81 | BRD4 (0.53) | BRD4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| US-9359548-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885EP300 15/4885BRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.